Physician
Dermatology
Dr. Seth P. Lerner, MD
|
|
Give Review
Seth Lerner is an expert in the field of Dermatology. He studied medicine at Boston University School of Medicine. Boston University School of Medicine is ranked 30/52 in Research/PrimaryCare. He received 6 awards: "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer", "Top MD", "Fellow (FAAD)" and "Fellow (FASDS)". Seth Lerner is a published doctor and has 93 publications published. The lastest was: 'Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature.' Seth P. Lerner is registered with Medicare.
Publications
- Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature.
- Novel neoadjuvant therapy paradigms for bladder Cancer: Results from the National Cancer Center Institute Forum.
- Examining sexual dysfunction in non-muscle-invasive bladder Cancer: results of cross-sectional mixed-methods research.
- The preclinical activity of lenalidomide in indolent urothelial Carcinoma.
- The angiopoietin-tie2 pathway is a potential therapeutic target in urothelial Carcinoma.
- Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial Carcinoma correlates inversely with homologous recombination repair response to DNA damage.
- Educational Opportunities in Bladder Cancer: Increasing Cystoscopic Adherence and the Availability of Smoking-Cessation Programs.
- Optimizing bladder Cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710.
- Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis.
- Urinary diversion after radical cystectomy for bladder Cancer: options, patient selection, and outcomes.
- SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus...
- Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy.
- Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial Cancer: a report from the Bladder Cancer Advocacy Network Clinical Tri...
- Variables affecting long-term maintenance of renal function following ileal based urinary diversion.
- Highlights of the 2010 SUO Annual Meeting.
- A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer.
- Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status.
- A genome-wide association study of bladder Cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3.
- Positive margins after radical prostatectomy: Implications for failure and role of adjuvant treatment.
- A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial Carcinoma.
- Critical analysis and validation of lymph node density as prognostic variable in urothelial Carcinoma of bladder.
- Prognostic risk stratification of pathological stage T3N0 bladder Cancer after radical cystectomy.
- Fluorescence and white light cystoscopy for detection of Carcinoma in situ of the urinary bladder.
- Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder Cancer.
- Prognostic risk stratification of pathological stage T2N0 bladder Cancer after radical cystectomy.
- The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial Carcinoma of the urinary bladder.
- Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.
- Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients.
- Characteristics and outcomes of patients with clinical Carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
- Dasatinib is preclinically active against Src-overexpressing human transitional Cell carcinoma of the urothelium with activated Src signaling.
- BCAN Think Tank session 3: Prevention of bladder Cancer.
- Bladder Cancer detection, treatment and outcomes: opportunities and challenges.
- Overview of SUO Winter 2008 proceedings.
- Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder Cancer.
- Characteristics and outcomes of patients with pT4 urothelial Carcinoma at radical cystectomy: a retrospective international study of 583 patients.
- Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder Cancer after neoadjuvant chemotherapy.
- p53 predictive value for pT1-2 N0 disease at radical cystectomy.
- The role and extent of pelvic lymphadenectomy in the management of patients with invasive urothelial Carcinoma.
- Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder Cancer.
- Sunitinib malate is active against human urothelial Carcinoma and enhances the activity of cisplatin in a preclinical model.
- Enzastaurin shows preclinical antitumor activity against human transitional Cell carcinoma and enhances the activity of gemcitabine.
- Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle ...
- Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder Cancer.
- Prostatic biology, histologic patterns and clinical consequences of transitional Cell carcinoma.
- Pathologic assessment and clinical significance of prostatic involvement by transitional Cell carcinoma and prostate cancer.
- Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder Cancer.
- Multiple biomarkers improve prediction of bladder Cancer recurrence and mortality in patients undergoing cystectomy.
- Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder Cancer.
- Molecular markers in bladder Cancer.
- Neoadjuvant chemotherapy for bladder Cancer.
- The use and abuse of data: nomograms and talking to patients about clinical medicine.
- Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional Cell carcinoma.
- Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder Cancer.
- Outcomes of radical cystectomy for transitional Cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
- Nomograms provide improved accuracy for predicting survival after radical cystectomy.
- Nomogram for predicting disease recurrence after radical cystectomy for transitional Cell carcinoma of the bladder.
- Characteristics and outcomes of patients with Carcinoma in situ only at radical cystectomy.
- Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
- Treatment of high-risk, non-muscle-invasive bladder Cancer.
- Advances in diagnosis and therapy of transitional Cell carcinoma of the bladder.
- Expression of estrogen receptors-alpha and -beta in bladder cancer Cell lines and human bladder tumor tissue.
- Clinical outcomes following radical cystectomy for primary nontransitional Cell carcinoma of the bladder compared to transitional Cell carcinoma of the bladder.
- Prostatic involvement by transitional Cell carcinoma in patients with bladder cancer and its prognostic significance.
- Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.
- Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph no...
- Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer.
- Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult.
- Bladder Cancer clinical trials.
- Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-Cell carcinoma of the urinary bladder.
- Polymorphisms in XPD exons 10 and 23 and bladder Cancer risk.
- Case-control analysis of dietary folate and risk of bladder Cancer.
- Dietary carotenoids and genetic instability modify bladder Cancer risk.
- Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional Cell carcinoma Cell line TSU-Pr1.
- Alternatives to cytology in the management of non-muscle invasive bladder Cancer.
- Stage specific lymph node metastasis mapping in radical cystectomy specimens.
- p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder Cancer.
- Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder Cancer.
- Granulocyte colony-stimulating factor receptor signals for beta1-integrin expression and adhesion in bladder Cancer.
- Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy.
- The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder Cancer.
- Centrosomal abnormality is common in and a potential biomarker for bladder Cancer.
- Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional Cell carcinoma of the bladder.
- Association of p53 and p21 expression with clinical outcome in patients with Carcinoma in situ of the urinary bladder.
- Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional Cell carci...
- Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder Cancer in vitro.
- Bladder Cancer screening program for a petrochemical cohort with potential exposure to beta-napthylamine.
- Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional Cell carcinoma of the bladder.
- Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder Cancer risk.
- Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder Cancer.
- Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder Carcinoma.
- Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder Cancer.
- Metastatic transitional Cell carcinoma of the urinary bladder to the shoulder girdle.
Schools
Boston University School Of Medicine
Li Jewish Hospital
University Ia Hosps
Procedures Preformed
- Adjacent Tissue Transfer
- Destruction of Benign Skin Lesion
- Destruction of Malignant Skin Lesion
- Excision of Benign Skin Lesion
- View All
Conditions Treated
- Acne
- Actinic Keratosis
- Athlete's Foot
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Dermatology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Top MD
- Fellow (FAAD)
- Fellow (FASDS)
Education
-
University of Iowa Hospitals and Clinics -
North Shore-Long Island Jewish Health System -
Boston University School of Medicine
Drug Facts
| NPI NUMBER | 1174548838 | |
| NPPES Provider LastName | LERNER | |
| NPPES Provider FirstName | SETH | |
| NPPES Provider ZIPCode | 066115300 | |
| NPPES Provider State | CT | |
| Specialty Description | Dermatology | |
| Total Claim Count | 829.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1174548838 |
| Last Name Of The Provider | LERNER |
| First Name Of The Provider | SETH |
| View All |
Similar Doctors
|
|
Dr. Mark I. Oestreicher, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dennis L. Feinberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert J. Patrignelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nira R. Silverman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason M. Wilder, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael P. Noonan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Deirdre B. Cannon, PA-C
This Doctor is OpenDoctor Recommended.
|